Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Trial ID or NCT#

NCT00382070

Status

not recruiting iconNOT RECRUITING

Purpose

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.

Official Title

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Eligibility Criteria

Ages Eligible for Study: 18 to 120
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Exclusion Criteria:
View All Criteria
Show Less

Investigator(s)

Frederick M. Dirbas, MD
Frederick M. Dirbas, MD
Breast specialist, Breast surgeon, Surgical oncologist
Associate Professor of Surgery (General Surgery) and, by courtesy, of Radiation Oncology (Radiation Therapy)
Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.
Medical oncologist, Breast specialist, Cancer geneticist
Colleen Haas Chair in the School of Medicine, Professor of Medicine (Oncology) and of Epidemiology and Population Health
Irene L Wapnir
Irene L Wapnir
Surgical oncologist, Breast surgeon, Breast specialist
Professor of Surgery (General Surgery)

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov